Mitsubishi Chemical Group (4188) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
17 Dec, 2025Executive summary
Sales revenue for the nine months ended Dec. 31, 2024, increased 3% year-over-year to JPY 3,331.5 billion, with core operating income up 34% to JPY 247.2 billion, driven by strong display and semiconductor-related sales and cost reductions.
Net income attributable to owners fell 43% year-on-year to JPY 59.4 billion, mainly due to business structure reform expenses, despite exceeding the full-year forecast.
The business environment remained stable overall, with robust demand in display and semiconductor sectors, but sluggish sales in automotive and food-related markets.
Financial highlights
Sales revenue for the first three quarters was JPY 3,331.5 billion, up 3% year-on-year, with a positive FX impact of JPY 98 billion.
Core operating income reached JPY 247.2 billion, up 34% year-on-year, and operating income was JPY 189.5 billion.
Net income attributable to owners was JPY 59.4 billion, down JPY 44.5 billion year-on-year, but above the revised full-year forecast.
Free cash flow for the period was JPY 131.8 billion, with net cash from operating activities at JPY 161.5 billion and net cash used in investing activities at JPY 211.0 billion.
Net interest-bearing debt decreased by JPY 43 billion to JPY 2,000.3 billion; net D/E ratio improved to 1.11.
Outlook and guidance
Full-year core operating income forecast is reiterated at JPY 290 billion, with net income guidance unchanged at JPY 52 billion, reflecting anticipated Q4 headwinds in MMA monomer price gap and seasonal factors.
Dividend forecast remains unchanged at JPY 16 per share for year-end and JPY 32 for the annual total.
Q4 is expected to see lower profits across most segments due to seasonal demand declines and cost concentration.
Ongoing focus on portfolio transformation and profit improvement under the Medium-term Management Plan 2029.
Latest events from Mitsubishi Chemical Group
- Net income surged on asset sales, but profit guidance was cut due to restructuring losses.4188
Q3 20265 Feb 2026 - Sales and core operating income surged, but net income fell; major structural reforms underway.4188
Q1 20252 Feb 2026 - Core operating income surged in H1 FY2024, but net income dropped on restructuring and special items.4188
Q2 202517 Jan 2026 - Core operating income up 43%, net income down 62%, with major portfolio reforms and Pharma divestiture.4188
Q4 202518 Nov 2025 - Specialty materials and semiconductors outperformed as profits fell; full-year outlook steady.4188
Q1 202616 Nov 2025 - Net income soared on one-time gains, but MMA weakness and restructuring weighed on results.4188
Q2 20262 Nov 2025